Role of ROS1 fusion gene mutations in diagnosis and treatment of non-small cell lung cancer / 中国肿瘤临床

The incidence of ROS1 gene rearrangement/fusion in non-small cell lung cancer (NSCLC) is about 1%-2%. The advent of tar-geted drugs for ROS1 gene fusion has significantly improved the quality of life and total survival of NSCLC patients with ROS1 fusion;however, acquired drug resistance is still present in most patients after continuous treatment. This review has summarized the back-ground of the ROS1 fusion gene, detection method, clinical efficacy of ROS1-targeted therapy, and strategy and prospect of drug resis-tance.